Treatment with low‐dose, single‐agent belantamab mafodotin is safe and provides long‐term responses in heavily pretreated multiple myeloma patients DOI Creative Commons
Irit Avivi, Tamir Shragai, Efrat Luttwak

et al.

European Journal Of Haematology, Journal Year: 2023, Volume and Issue: 112(3), P. 367 - 370

Published: Oct. 26, 2023

Abstract Objectives To evaluate whether low‐dose belantamab mafodotin (B‐MAF) dosing results in lower toxicity and better overall outcome. Methods We retrospectively evaluated nine consecutive patients treated with (1.9 mg/kg) B‐MAF. Results The median age was 70 years. Most were penta‐refractory. Ocular observed 77.7%. Adverse events resulting treatment delays recorded 9 out of 124 cycles being given. Overall response rate 66% (6/9), all responding achieved very good partial or better. Within a follow‐up 12 (range 0.5–13.8) months, progression‐free survival 14 (CI95% 6–22) 20 (95%CI 0–41) respectively. Conclusion Low‐dose B‐MAF regimen showed high‐efficacy low‐toxicity profile.

Language: Английский

A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma DOI Creative Commons

Rachel Dileo,

Prerna Mewawalla,

Kalaivani Babu

et al.

Blood Cancer Journal, Journal Year: 2025, Volume and Issue: 15(1)

Published: March 10, 2025

Abstract While initial trials led to the accelerated approval of belantamab mafodotin, a BCMA-directed antibody-drug conjugate, confirmatory failed establish benefit from this therapy for patients with relapsed refractory multiple myeloma (RRMM), eventually leading its withdrawal commercial use. With an imminent as effective combination therapy, seen in recent randomized trials, we report real-world clinical outcomes mafodotin 81 RRMM patients. median 5 (range 2–15) prior lines 92, 45, and 15% were triple-class refractory, penta-class BCMA-refractory. More than half (57%) had high-risk cytogenetics, 37% extramedullary disease (EMD), 67% would have been considered ineligible DREAMM-2 trial. The best overall response (ORR) complete rates 40.0 15.0%, respectively. ORRs lower EMD, BCMA-refractory, penta-refractory at 23, 17, 24%, All-grade ocular toxicity was 69% patients, grade 3+ events 43%. Grade hematological toxicities included neutropenia (20%), anemia (28%), thrombocytopenia (31%). follow-up 11.3 (0.3–44.6) months entire population, PFS OS (1–20) 12 (3–28) months, Presence EMD only predictor both on multivariable analysis. Compared pivotal trial despite several features, demonstrated comparable efficacy safety patient population.

Language: Английский

Citations

0
Individualized dynamic risk assessment and treatment selection for multiple myeloma DOI
Carl Murie, Serdar Turkarslan, Anoop P. Patel

et al.

British Journal of Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
Treatment patterns, efficacy, and tolerability of belantamab mafodotin in patients with relapsed and/or refractory multiple myeloma: a real-world analysis DOI
Mihir Patel, Susan C. Locke,

Caroline Falvey

et al.

Clinical Lymphoma Myeloma & Leukemia, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study DOI Creative Commons
Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos

et al.

Haematologica, Journal Year: 2024, Volume and Issue: unknown

Published: Feb. 15, 2024

Preclinical and clinical data demonstrate synergy between belantamab mafodotin (belamaf) immunomodulatory drugs with limited overlapping toxicities. We investigated the safety efficacy of belamaf lenalidomide 25mg on days 1-21 every 28 dexamethasone 40mg weekly (belamaf-Rd) in transplant ineligible patients newly diagnosed multiple myeloma. 36 (median age 72.5 years) were randomized to receive at three different doses (2.5/1.9/1.4 mg/kg) 8 weeks (q8w). Dosing schedule was extended 12 (q12w) account for ocular toxicity. Most common ≥ Grade (Gr) 3 adverse events fatigue (n=21, 58.3%), rash (n=6, 16.7%), diarrhea (n=8, 22.2%) COVID-19 (n=5, 13.9%). Gr 3-4 (OAEs), comprising visual acuity decline from baseline and/or keratopathy, reported 39/216(18.1%)/ 33/244(13.5%)/ 26/207(12.6%) ophthalmological assessments cohorts 2.5/1.9/1.4 mg/kg. Importantly, keratopathy identified 9/216 (4.2%)/ 1/244(0.4%)/ 1/207(0.5%) assessments. (32/36, 88.9%) treated q12w schedule, where dose holds due OAEs 40, 33 16 2.5/1.9/1.4. Overall, ≥VGPR ≥CR rates 83.3% 52.8%, without significant differences among cohorts. Over a median follow-up 20.3 months no disease progression reported; 6 discontinued treatment infection-related death (n=4 COVID-19, n=2 pneumonia) 1 patient withdrew consent. Based toxicity/efficacy balance, recommended phase 2 1.9 mg/kg q8w, Belamaf-Rd, belamaf, has shown important activity improvement minimal impact vision-related functioning an elderly, non-transplant eligible population.

Language: Английский

Citations

2
Belantamab mafodotin in triple‐refractory multiple myeloma patients: A retro‐prospective observational study in Italy DOI Creative Commons
Francesca Fazio, Maria Teresa Petrucci,

Laura Corvatta

et al.

eJHaem, Journal Year: 2024, Volume and Issue: 5(3), P. 485 - 493

Published: April 30, 2024

Abstract Belantamab mafodotin is the first‐in‐class antibody‐drug conjugates targeting B‐cell maturation antigen to have demonstrated effectiveness in triple‐class refractory multiple myeloma (TCR‐MM) patients. We performed a retrospective study including 78 TCR patients, with at least four prior lines of therapy (LOTs), who received belantamab within named patient program and expanded access Italy between 2020 2022. Median age was 65 years (range 42–86 years), ECOG performance status ≥1 45% Overall, clinical benefit obtained 36 out 74 evaluable patients (49%), 43%, 28%, 13.5% achieving partial response, very good complete respectively. After median follow‐up 12 months 6–21 months), duration progression‐free survival (PFS), overall (OS) were 14, 5.5, months, Age >70 years, response associated longer PFS OS. Keratopathy occurred 58% (G3 2.5%), corneal symptoms 32% 1.2%) reduction visual acuity 14%. Grade 3 thrombocytopenia 9% Only 3% discontinued because side effects. This real‐life significant durable responses TCR‐MM LOTs, otherwise ineligible for novel immunotherapies.

Language: Английский

Citations

2
Belantamab mafodotin, lenalidomide, and dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin‐associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study DOI Open Access
Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis

et al.

American Journal of Hematology, Journal Year: 2024, Volume and Issue: 99(3), P. 502 - 504

Published: Jan. 25, 2024

Language: Английский

Citations

1
Characteristics of isatuximab-derived interference in serum protein electrophoresis and immunofixation, and an absence of sustained in vivo interference due to belantamab mafodotin and denosumab DOI
Adam Jimenez, Ashley Rose Scholl, Bangchen Wang

et al.

Clinical Biochemistry, Journal Year: 2024, Volume and Issue: 127-128, P. 110761 - 110761

Published: March 31, 2024

Language: Английский

Citations

1
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma DOI Creative Commons
María‐Victoria Mateos, Katja Weisel, Evangelos Terpos

et al.

Haematologica, Journal Year: 2024, Volume and Issue: unknown

Published: Feb. 22, 2024

Not available.

Language: Английский

Citations

0
Infections during novel myeloma therapies DOI
Alice Liu, Monica A. Slavin, Simon J. Harrison

et al.

Leukemia & lymphoma/Leukemia and lymphoma, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 13

Published: Nov. 18, 2024

New generation therapies such as bispecific antibodies (BsAb), chimeric antigen receptor T-cell therapy (CAR T) and antibody-drug conjugates (ADC) have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM). However, there is emerging evidence increased infection risk associated with these treatments in clinical trials observational settings. This may be mediated by on-target, off-tumor side effects cytokine release syndrome, hypogammaglobulinaemia cytopenias, disease-related humoral impairment consequences previous lines treatment. While bacterial viral pathogens predominate, reactivation latent opportunistic infections also warrant attention. review characterizes epidemiology novel for RRMM to guide prophylaxis antimicrobial prescribing this patient population highlights future areas focus inform ongoing prevention strategies.

Language: Английский

Citations

0
A Real-World Experience of Efficacy and Safety of Belantamab Mafodotin in Relapsed Refractory Multiple Myeloma DOI Creative Commons
Hamza Hashmi,

Rachel Dileo,

Prerna Mewawalla

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 19, 2024

Abstract While initial trials led to the accelerated approval of belantamab mafodotin, a BCMA directed antibody drug conjugate, confirmatory failed establish benefit from this therapy for patients with relapsed refractory multiple myeloma (RRMM), eventually leading its withdrawal commercial use. With an imminent as effective combination seen in recent randomized trials, we report real-world clinical outcomes mafodotin 81 RRMM patients. median 5 (range 2–15) prior lines therapy, 92%, 45%, and 15% were triple-class refractory, penta-class BCMA-refractory. More than half (57%) had high-risk cytogenetics, 37% extramedullary disease (EMD), 67% would have been considered ineligible DREAMM-2 trial. Best overall response (ORR) complete rates 40.0% 15.0%, respectively. ORRs lower EMD, BCMA-refractory penta-refractory at 23%, 17%, 24%, All grade ocular toxicity was 69% 3 + events 43%. Grade hematological toxicities included neutropenia (20%), anemia (28%), thrombocytopenia (31%). follow-up 11.3 (0.3–44.6) months entire population, PFS OS (1–20) 12 (3–28) months, Presence EMD only predictor both on multivariable analysis. Compared pivotal trial despite several features, demonstrated comparable efficacy safety patient population.

Language: Английский

Citations

0